KOSDAQBiotech & Pharma310210

Voronoi

₩102,400▲ 1.29%2026-11-18 close
Market Cap
₩1.9T
Turnover
₩6.8B
Volume
60K
Shares out.
18.6M
PER
—
PBR
34.9×
EPS
-₩4,676
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Brain-metastasis data draws attention; accumulated losses are the test

Voronoi is building its case on VRN11 resistance and brain-metastasis data and on milestone income from the VRN07 licensing deal, but operating losses have widened every year since 2022 and fourth-quarter 2025 revenue fell to KRW 22.06 million.

  1. 1

    VRN11 data presented at WCLC and ESMO in September 2026 covered C797S-resistant patients and patients with brain metastases. These are Phase 1 results with small cohorts (6 and 19 patients).

  2. 2

    The 2025 operating loss was KRW 54.4 billion, and the company has posted losses for four consecutive years from 2022. The operating margin fell from -182.9% in 2022 to -723.9% in 2025.

  3. 3

    Losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. Net loss attributable to controlling shareholders over the last four quarters totals KRW 85.8 billion.

  4. 4

    Hyundai Motor Securities presented a BUY rating and a target price of KRW 230,000 in its September 18, 2026 report. Yuanta Securities maintained its buy rating and KRW 450,000 target price in its September 17, 2026 report.

  5. 5

    Voronoi decided on November 13, 2026 to issue KRW 52.7 billion in convertible bonds, with payment due November 23. The company said the proceeds will go mainly to global trials for VRN11 and other core pipeline assets.

02

Business structure

Voronoi is a clinical-stage oncology drug developer whose value rests on its pipeline and licensing results rather than on product sales.

Its three core candidates are VRN11, an EGFR-mutant non-small cell lung cancer drug now in global Phase 1b/2 trials; VRN10, a HER2-mutant and HER2-positive solid tumor drug planned to enter Phase 1b in 2027; and VRN07 (enozertinib, development code ORIC-114).

VRN07 was licensed to Oric Pharmaceuticals of the United States in 2020, and the development milestones disclosed under that deal total up to USD 158 million. A 2024 press report indicated that Voronoi still held the Greater China rights.

Past revenue came mainly from licensing milestones, so quarterly revenue moves sharply with milestone timing. Oric leads the later-stage VRN07 program, and analysts have pointed to a planned combination with amivantamab from Janssen.

In EGFR-mutant lung cancer, the third-generation drug osimertinib (Tagrisso) is the standard of care, and VRN11 targets patients with the C797S resistance mutation and brain metastases.

In HER2-mutant lung cancer, VRN10 is compared with zongertinib and savabertinib, and the company highlights its blood-brain barrier penetration. In March 2026 shareholders approved an audit committee, and outside directors now make up 50% of the board.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.1B-₩13.6B−327.6%
2025Q4₩22,056,000-₩16.2B−73336.0%
2026Q1₩0-₩22B—
2026Q2₩0-₩29.3B—
2026Q3₩0-₩29.2B—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.8B-₩17.9B-₩19.9B−182.9%−58.1%86.7%
2023₩0-₩31.3B-₩36.8B—−45.3%16.4%
2024₩0-₩36.3B-₩32.6B—−49.1%10.9%
2025₩7.5B-₩54.4B-₩42.7B−723.9%−41.1%65.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a reported basis, Voronoi's revenue has shrunk while its operating losses have grown each year. Revenue fell from KRW 9.77 billion in 2022 to KRW 7.51 billion in 2025; no revenue figures are reported for 2023 and 2024, so those years are left out of the comparison.

Operating loss rose from KRW 17.9 billion in 2022 to KRW 31.3 billion in 2023, KRW 36.3 billion in 2024 and KRW 54.4 billion in 2025. The operating margin fell from -182.9% in 2022 to -723.9% in 2025, reflecting falling sales and widening losses at the same time.

Net loss attributable to controlling shareholders was KRW 19.9 billion in 2022, KRW 36.8 billion in 2023, KRW 32.6 billion in 2024 and KRW 42.7 billion in 2025. In 2024 that loss narrowed while the operating loss widened, so the two measures moved in opposite directions.

Net loss including non-controlling interests was reported at the same amounts each year. Operating cash flow went from negative KRW 16.3 billion in 2022 to negative KRW 72.1 billion in 2025.

The debt-to-equity ratio rose from 10.9% in 2024 to 65.0% in 2025, when total liabilities were KRW 67.4 billion against total equity of KRW 103.8 billion. The quarterly pattern points the same way.

Revenue of KRW 4.14 billion in the third quarter of 2025 dropped to KRW 22.06 million in the fourth quarter, a decline of 99.5% from the prior quarter.

Operating loss moved from KRW 13.6 billion in the third quarter of 2025 to KRW 16.2 billion, KRW 22 billion, KRW 29.3 billion and KRW 29.2 billion through the third quarter of 2026.

Net loss attributable to controlling shareholders reached KRW 30.5 billion in the third quarter of 2026, against KRW 13.8 billion a year earlier.

In the fourth quarter of 2025 the operating loss was KRW 16.2 billion while the net loss attributable to controlling shareholders was KRW 4.31 billion, so non-operating items had a large effect in that quarter.

05

Industry analysis

The EGFR-mutant non-small cell lung cancer market has third-generation targeted therapies as its standard of care, and resistance mutations and brain metastases remain the unmet needs.

Conference data describe C797S as a leading resistance route after third-generation treatment, and patients who develop brain metastases have limited follow-on options. Voronoi highlights VRN11's ability to cross the blood-brain barrier and supports this with intracranial response data.

In a September 17, 2026 report, Yuanta Securities described VRN11 as showing high target selectivity and blood-brain barrier penetration in early clinical data. The same report noted that early trials carry limits because many patients have prior treatment lines and high heterogeneity.

In HER2-mutant lung cancer, zongertinib and savabertinib are the comparators, and Yuanta assessed VRN10's tolerability as superior to both. The same report judged zongertinib to have limited central nervous system reach due to low blood-brain barrier penetration.

In first-line treatment, Janssen's amivantamab is named as the combination partner for the VRN07 Phase 3, and analysts stress that Janssen already holds an approved first-line therapy.

The company said in its November 2026 bond announcement that investor sentiment in biotech has weakened under global financial uncertainty. In development stage terms, VRN11 is in global Phase 1b/2 trials and VRN07 is in preparation for a Phase 3 led by Oric, so both programs are moving up the clinical ladder.

06

Outlook

Voronoi's confirmed schedule has three threads. First, VRN11 is running global Phase 1b/2 trials in Australia, Hong Kong, Singapore, Malaysia and Thailand, and the Thai trial application was approved and disclosed on September 14, 2026.

Second, VRN11's Canadian trial application was voluntarily withdrawn on September 9, 2026 to reflect the regulator's review comments, and the company said it plans to resubmit after updating the data.

Third, a corrective disclosure on October 20, 2026 added France and Spain as European trial countries for the VRN11 Phase 1/2 study.

On first-line treatment, a late-2025 press report set a target of starting a first-line trial in treatment-naive patients in the first half of 2026; whether it has started and what interim results show should be checked against later disclosures and conference presentations. VRN10 is planned to enter Phase 1b in 2027.

For VRN07, Oric has completed end-of-Phase 1 discussions with the US FDA and plans to start the global Phase 3 Redwood-1 in the first half of 2027. The development milestones Voronoi could receive total up to USD 158 million and are paid as stages are reached.

On funding, the KRW 52.7 billion convertible bond has a 0% coupon, a 2% yield to maturity, and a November 23, 2031 maturity, with a conversion price of KRW 111,510 per share. The floor for conversion price adjustments if the share price falls is set at 70% of the original conversion price.

The 2026 annual report, the next periodic filing, will show whether the annual loss and cash burn change from 2025.

07

Valuation

PER
—
PBR
34.9×
ROE
-153.7%
EPS
-₩4,676
BPS
₩3,182
Dividend per share
₩0

Earnings-based multiples cannot be calculated because net losses over the last four quarters leave no positive earnings base. Valuation therefore has to be read against net assets and pipeline expectations.

The price-to-book ratio sits at a large premium to net assets, even within the biotech group, which means a significant share of the share price reflects expectations for clinical success and licensing deals. Dividend income is effectively absent.

Market capitalization is several dozen times the 2025 operating loss, so the pipeline's future value explains more of the share price than current earnings do.

In September 2026, Hyundai Motor Securities presented a BUY rating with a KRW 230,000 target price, and Yuanta Securities kept its buy rating with a KRW 450,000 target. The two targets are different levels.

Both were issued about two months ago, so later share-price moves and any target revisions should be read alongside them.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

VRN11 resistance and brain-metastasis data

All six patients with the C797S resistance mutation who received 160 mg or more showed an objective response, and their median progression-free survival was reported at 11 months.

Among 19 patients with brain metastases, intracranial disease control reached 100%, and four patients (21%) had complete intracranial responses. The sample is small and Phase 1, but the data come from a group with limited follow-on options, which is the main argument for its relevance.

Milestone potential from VRN07

Oric has completed end-of-Phase 1 discussions with the FDA and plans to start a global Phase 3 in the first half of 2027. The development milestones disclosed by Voronoi total up to USD 158 million, so income could arise as each stage is reached. The 2020 deal was valued at USD 620 million in total.

Pipeline expansion and trial funding

Thailand's approval of the VRN11 trial application added a country to the global Phase 1b/2 network, and France and Spain were added as European trial countries. Yuanta noted that no dose-limiting toxicity was identified in 67 patients dosed with VRN10 from 10 mg to 480 mg. The KRW 52.7 billion convertible bond issued in November 2026 adds funding for the trials.

09

Bear factors

Revenue gap and widening losses

Operating loss widened from KRW 17.9 billion in 2022 to KRW 54.4 billion in 2025, while revenue shrank from KRW 9.77 billion to KRW 7.51 billion over the same period. Fourth-quarter 2025 revenue was KRW 22.06 million, and no revenue data are reported for the first through third quarters of 2026. Operating losses have now continued for five consecutive quarters from the third quarter of 2025.

Cash burn and dilution risk

Operating cash flow went from negative KRW 16.3 billion in 2022 to negative KRW 72.1 billion in 2025. Total equity stood at KRW 103.8 billion at the end of 2025.

The KRW 52.7 billion convertible bond issued in November 2026 has a conversion price of KRW 111,510 per share, and if the share price falls the adjustment floor is set at 70% of that price, which could increase the number of shares.

Early-stage data and partner dependence

Yuanta also pointed to the limits of early data, where many patients have multiple prior treatments and high heterogeneity. The timing of VRN07 development and milestone payments depends on Oric's schedule.

The Canadian trial application for VRN11 was voluntarily withdrawn in September 2026, and no resubmission timeline has been set out in a disclosure yet.

10

Risk factors

Clinical and regulatory

Canada's health regulator asked for updated investigator documentation, prompting Voronoi to voluntarily withdraw the VRN11 trial application on September 9, 2026. Even as data accumulate, regulatory requests can delay timelines. Because Phase 1 cohorts are small, later trial results may differ from the early figures.

Funding and dilution

The KRW 52.7 billion convertible bond carries a 0% coupon, a 2% yield to maturity, and matures on November 23, 2031, with payment due November 23. Conversion would increase the number of shares outstanding.

With operating cash flow at negative KRW 72.1 billion in 2025, rising trial costs could increase the need for further funding.

Governance and disclosure

On September 9, 2026, a stock option disclosure for the chief medical officer omitted its exercise conditions, and the company issued a correction after a press release. The option can be exercised only if enterprise value reaches KRW 30 trillion or more and a change of control occurs. A 2025 press report said the CEO was in a lawsuit with a securities firm over a share-backed loan.

11

What to watch next

  1. November 23, 2026

    Payment date for the KRW 52.7 billion convertible bond. The pace of trial spending funded by the proceeds and the effect of the KRW 111,510 conversion price and adjustment floor on the future share count are the points to track.

  2. First half of 2027

    Expected start of Oric's global Phase 3 trial Redwood-1 for VRN07. The start of Phase 3 is linked to the staged development milestones Voronoi is due to receive.

  3. By the end of March 2027

    Deadline for the 2026 annual report. It will show how the 2026 annual operating loss, operating cash flow and debt-to-equity ratio compare with the 2025 figures, making it the next reported earnings checkpoint.

  4. 2027 (timing not set)

    Entry of VRN10 into Phase 1b and the resubmission of the VRN11 Canadian trial application are both pending. Their timing will be confirmed through disclosures once set.

12

Overall view

Voronoi's reported results show revenue falling from KRW 9.77 billion in 2022 to KRW 7.51 billion in 2025 while the operating loss widened to KRW 54.4 billion.

Losses have continued for five consecutive quarters from the third quarter of 2025, and net loss attributable to controlling shareholders over the last four quarters totals KRW 85.8 billion.

On the positive side, the discussion centers on VRN11 data in C797S-resistant and brain-metastasis patients and on possible development milestones tied to the VRN07 Phase 3. On the negative side, the main points are the revenue gap, a larger operating cash burn and the possibility of dilution from convertible bonds.

Target prices presented in September 2026 differ between Hyundai Motor Securities at KRW 230,000 and Yuanta Securities at KRW 450,000. The next checkpoints are the November 23 bond payment, the start of the VRN07 Phase 3 in the first half of 2027, and the 2026 annual report due by the end of March 2027. The key question is whether the operating loss and operating cash flow in that report follow the 2025 trend.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. getnews.co.kr
  2. markets.hankyung.com
  3. news.nate.com
  4. m.news.nate.com
  5. m.news.nate.com
  6. paxnet.co.kr
  7. pharm.edaily.co.kr
  8. msn.com
  9. m.news.nate.com
  10. youtube.com
  11. v.daum.net
  12. newspim.com
  13. pharm.edaily.co.kr
  14. mt.co.kr
  15. dealsite.co.kr
  16. sentv.co.kr
  17. m.news.zum.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis